Tuberous sclerosis complex (TSC) is a dominant autosomal genetic disorder caused by loss-of-function mutations in TSC1 and TSC2, which lead to constitutive activation of the mammalian target of rapamycin C1 (mTORC1) with its decoupling from regulatory inputs. Because mTORC1 integrates an array of molecular signals controlling protein synthesis and energy metabolism, its unrestrained activation inflates cell growth and division, resulting in the development of benign tumors in the brain and other organs. In humans, brain malformations typically manifest through a range of neuropsychiatric symptoms, among which mental retardation, intellectual disabilities with signs of autism, and refractory seizures, which are the most prominent. TSC in the rat brain presents the first-rate approximation of cellular and molecular pathology of the human brain, showing many instructive characteristics. Nevertheless, the developmental profile and distribution of lesions in the rat brain, with neurophysiological and behavioral manifestation, deviate considerably from humans, raising numerous research and translational questions. In this study, we revisit brain TSC in human and Eker rats to relate their histopathological, electrophysiological, and neurobehavioral characteristics. We discuss shared and distinct aspects of the pathology and consider factors contributing to phenotypic discrepancies. Given the shared genetic cause and molecular pathology, phenotypic deviations suggest an incomplete understanding of the disease. Narrowing the knowledge gap in the future should not only improve the characterization of the TSC rat model but also explain considerable variability in the clinical manifestation of the disease in humans.

Department of Experimental Neurobiology National Institute of Mental Health Topolová 748 250 67 Klecany Czech Republic

Department of Medical Genetics 3rd Faculty of Medicine of Charles University Ruská 87 100 00 Prague Czech Republic

Department of Psychiatry and Medical Psychology 3rd Faculty of Medicine of Charles University Ruská 87 100 00 Prague Czech Republic

Department of Psychological and Brain Sciences Indiana University Bloomington IN USA

Zobrazit více v PubMed

Ryskalin L, et al. mTOR-Dependent Cell Proliferation in the Brain. Biomed Res Int. 2017;2017:7082696. doi: 10.1155/2017/7082696. PubMed DOI PMC

Crino, P.B., mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med, 2015. 5(4):a022442. 10.1101/cshperspect.a022442. PubMed PMC

Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;169(2):361–371. doi: 10.1016/j.cell.2017.03.035. PubMed DOI

Dentel B, Escamilla CO, Tsai PT. Therapeutic Targeting of mTORC2 in mTORopathies. Neuron. 2019;104(6):1032–1033. doi: 10.1016/j.neuron.2019.11.026. PubMed DOI

Richardson EP., Jr Pathology of tuberous sclerosis. Neuropathologic aspects. Ann N Y Acad Sci. 1991;615:128–139. doi: 10.1111/j.1749-6632.1991.tb37755.x. PubMed DOI

Vinters HV, et al. Cortical dysplasia, genetic abnormalities and neurocutaneous syndromes. Dev Neurosci. 1999;21(3-5):248–259. doi: 10.1159/000017404. PubMed DOI

Eker R. Familial renal adenomas in Wistar rats; a preliminary report. Acta Pathol Microbiol Scand. 1954;34(6):554–562. doi: 10.1111/j.1699-0463.1954.tb00301.x. PubMed DOI

Eker R, et al. Hereditary renal adenomas and adenocarcinomas in rats. Diagn Histopathol. 1981;4(1):99–110. PubMed

Yeung RS, Katsetos CD, Klein-Szanto A. Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. Am J Pathol. 1997;151(5):1477–1486. PubMed PMC

Kutna V, et al. Tuberous Sclerosis (tsc2+/-) Model Eker Rats Reveals Extensive Neuronal Loss with Microglial Invasion and Vascular Remodeling Related to Brain Neoplasia. Neurotherapeutics. 2020;17(1):329–339. doi: 10.1007/s13311-019-00812-6. PubMed DOI PMC

Waltereit R, et al. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J Neurochem. 2006;96(2):407–413. doi: 10.1111/j.1471-4159.2005.03538.x. PubMed DOI

Rennebeck G, et al. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc Natl Acad Sci U S A. 1998;95(26):15629–15634. doi: 10.1073/pnas.95.26.15629. PubMed DOI PMC

Knudson AG., Jr Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–823. doi: 10.1073/pnas.68.4.820. PubMed DOI PMC

Tomlinson IP, Roylance R, Houlston RS. Two hits revisited again. J Med Genet. 2001;38(2):81–85. doi: 10.1136/jmg.38.2.81. PubMed DOI PMC

Afshar Saber W, Sahin M. Recent advances in human stem cell-based modeling of Tuberous Sclerosis Complex. Mol Autism. 2020;11(1):16. doi: 10.1186/s13229-020-0320-2. PubMed DOI PMC

Blair JD, Bateup HS. New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids. Dev Dyn. 2020;249(1):46–55. doi: 10.1002/dvdy.60. PubMed DOI PMC

Robertson, F.L., et al., Experimental models and tools to tackle glioblastoma. Dis Model Mech, 2019. 12(9):dmm040386. 10.1242/dmm.040386. PubMed PMC

Parsa AT, et al. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery. 2000;47(4):993–999. doi: 10.1097/00006123-200010000-00050. PubMed DOI

Workman P, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555–1577. doi: 10.1038/sj.bjc.6605642. PubMed DOI PMC

Simons, B.W. and C. Brayton, Challenges and Limitations of Mouse Xenograft Models of Cancer. Patient Derived Tumor Xenograft Models, ed. R. Uthamanthil and P. Tinkey. 2016, Johns Hopkins University School of Medicine, Baltimore, MD, United States: Academic Press.

Kim KM, et al. Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments. Cancer Cell Int. 2016;16:43. doi: 10.1186/s12935-016-0319-0. PubMed DOI PMC

Fryer AE, et al. Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet. 1987;1(8534):659–661. doi: 10.1016/S0140-6736(87)90416-8. PubMed DOI

van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–808. doi: 10.1126/science.277.5327.805. PubMed DOI

Kandt RS, et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet. 1992;2(1):37–41. doi: 10.1038/ng0992-37. PubMed DOI

Henske EP, et al. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. doi: 10.1038/nrdp.2016.35. PubMed DOI

Lam HC, Siroky BJ, Henske EP. Renal disease in tuberous sclerosis complex: pathogenesis and therapy. Nat Rev Nephrol. 2018;14(11):704–716. doi: 10.1038/s41581-018-0059-6. PubMed DOI

Bongaarts A, et al. Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget. 2017;8(56):95516–95529. doi: 10.18632/oncotarget.20764. PubMed DOI PMC

Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412(2):179–190. doi: 10.1042/BJ20080281. PubMed DOI PMC

Rosset C, Netto CBO, Ashton-Prolla P. TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review. Genet Mol Biol. 2017;40(1):69–79. doi: 10.1590/1678-4685-gmb-2015-0321. PubMed DOI PMC

Lamb RF, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol. 2000;2(5):281–287. doi: 10.1038/35010550. PubMed DOI

Haddad LA, et al. The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton. J Biol Chem. 2002;277(46):44180–44186. doi: 10.1074/jbc.M207211200. PubMed DOI

Schopel M, et al. The small GTPases Ras and Rheb studied by multidimensional NMR spectroscopy: structure and function. Biol Chem. 2017;398(5-6):577–588. doi: 10.1515/hsz-2016-0276. PubMed DOI

Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol. 2010;11(4):276–287. doi: 10.1038/nrm2866. PubMed DOI PMC

Kleijer KT, et al. Neurobiology of autism gene products: towards pathogenesis and drug targets. Psychopharmacology. 2014;231(6):1037–1062. doi: 10.1007/s00213-013-3403-3. PubMed DOI

Kobayashi T, et al. Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog. Mamm Genome. 1997;8(8):554–558. doi: 10.1007/s003359900502. PubMed DOI

Maheshwar MM, et al. The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum Mol Genet. 1997;6(11):1991–1996. doi: 10.1093/hmg/6.11.1991. PubMed DOI

Nussinov R, et al. The Mystery of Rap1 Suppression of Oncogenic Ras. Trends Cancer. 2020;6(5):369–379. doi: 10.1016/j.trecan.2020.02.002. PubMed DOI PMC

Jaskiewicz, A., B. Pajak, and A. Orzechowski, The Many Faces of Rap1 GTPase. Int J Mol Sci, 2018. 19(10):2848. 10.3390/ijms19102848. PubMed PMC

Rubinfeld B, et al. Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21rap1. Cell. 1991;65(6):1033–1042. doi: 10.1016/0092-8674(91)90555-D. PubMed DOI

Yeung RS. Lessons from the Eker rat model: from cage to bedside. Curr Mol Med. 2004;4(8):799–806. doi: 10.2174/1566524043359791. PubMed DOI

Soucek T, et al. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem. 1997;272(46):29301–29308. doi: 10.1074/jbc.272.46.29301. PubMed DOI

Jin M, An Q, Wang L. Importance of tuberin in carcinogenesis. Oncol Lett. 2017;14(3):2598–2602. doi: 10.3892/ol.2017.6490. PubMed DOI PMC

Rosner M, Hengstschlager M. Cytoplasmic/nuclear localization of tuberin in different cell lines. Amino Acids. 2007;33(4):575–579. doi: 10.1007/s00726-007-0541-0. PubMed DOI

Wienecke R, et al. Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene. 1996;13(5):913–923. PubMed

Demetriades C, Doumpas N, Teleman AA. Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell. 2014;156(4):786–799. doi: 10.1016/j.cell.2014.01.024. PubMed DOI PMC

Demetriades C, Plescher M, Teleman AA. Lysosomal recruitment of TSC2 is a universal response to cellular stress. Nat Commun. 2016;7:10662. doi: 10.1038/ncomms10662. PubMed DOI PMC

Johnson MW, et al. Hamartin and tuberin expression in human tissues. Mod Pathol. 2001;14(3):202–210. doi: 10.1038/modpathol.3880286. PubMed DOI

Li Y, et al. Regionally specific TSC1 and TSC2 gene expression in tuberous sclerosis complex. Sci Rep. 2018;8(1):13373. doi: 10.1038/s41598-018-31075-4. PubMed DOI PMC

Dan HC, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem. 2016;291(43):22848. doi: 10.1074/jbc.A116.205838. PubMed DOI PMC

Inoki K, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648–657. doi: 10.1038/ncb839. PubMed DOI

Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4(9):658–665. doi: 10.1038/ncb840. PubMed DOI

Tee AR, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–13576. doi: 10.1073/pnas.202476899. PubMed DOI PMC

Ma L, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007;67(15):7106–7112. doi: 10.1158/0008-5472.CAN-06-4798. PubMed DOI

Nie D, et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci. 2010;13(2):163–172. doi: 10.1038/nn.2477. PubMed DOI PMC

Han S, et al. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal. 2008;20(6):1084–1091. doi: 10.1016/j.cellsig.2008.01.020. PubMed DOI PMC

Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577–590. doi: 10.1016/S0092-8674(03)00929-2. PubMed DOI

Hahn-Windgassen A, et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem. 2005;280(37):32081–32089. doi: 10.1074/jbc.M502876200. PubMed DOI

Lee DF, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 2007;130(3):440–455. doi: 10.1016/j.cell.2007.05.058. PubMed DOI

Kwiatkowski DJ. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther. 2003;2(5):471–476. doi: 10.4161/cbt.2.5.446. PubMed DOI

Meikle L, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007;27(21):5546–5558. doi: 10.1523/JNEUROSCI.5540-06.2007. PubMed DOI PMC

Goncharova EA, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM) J Biol Chem. 2002;277(34):30958–30967. doi: 10.1074/jbc.M202678200. PubMed DOI

Cheadle JP, et al. Molecular genetic advances in tuberous sclerosis. Hum Genet. 2000;107(2):97–114. doi: 10.1007/s004390000348. PubMed DOI

Napolioni V, Curatolo P. Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics. 2008;9(7):475–487. doi: 10.2174/138920208786241243. PubMed DOI PMC

Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125–127. doi: 10.1111/j.1749-6632.1991.tb37754.x. PubMed DOI

Samueli S, et al. Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management. Wien Klin Wochenschr. 2015;127(15-16):619–630. doi: 10.1007/s00508-015-0758-y. PubMed DOI

Prather P, de Vries PJ. Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol. 2004;19(9):666–674. doi: 10.1177/08830738040190090601. PubMed DOI

de Vries PJ, et al. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND) Am J Med Genet C: Semin Med Genet. 2018;178(3):309–320. doi: 10.1002/ajmg.c.31637. PubMed DOI PMC

Gipson TT, et al. Potential for treatment of severe autism in tuberous sclerosis complex. World J Clin Pediatr. 2013;2(3):16–25. doi: 10.5409/wjcp.v2.i3.16. PubMed DOI PMC

Hunt A, Dennis J. Psychiatric disorder among children with tuberous sclerosis. Dev Med Child Neurol. 1987;29:190–198. doi: 10.1111/j.1469-8749.1987.tb02135.x. PubMed DOI

Holmes GL, Stafstrom CE, Tuberous Sclerosis G. Study, Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia. 2007;48(4):617–630. doi: 10.1111/j.1528-1167.2007.01035.x. PubMed DOI

Nabbout R, et al. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia Open. 2019;4(1):73–84. doi: 10.1002/epi4.12286. PubMed DOI PMC

Braffman BH, et al. MR imaging of tuberous sclerosis: pathogenesis of this phakomatosis, use of gadopentetate dimeglumine, and literature review. Radiology. 1992;183(1):227–238. doi: 10.1148/radiology.183.1.1549677. PubMed DOI

Ridler K, et al. Standardized whole brain mapping of tubers and subependymal nodules in tuberous sclerosis complex. J Child Neurol. 2004;19(9):658–665. doi: 10.1177/08830738040190090501. PubMed DOI

Peters JM, et al. Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions. Future Neurol. 2013;8(5):583–597. doi: 10.2217/fnl.13.37. PubMed DOI PMC

Yamanouchi H, et al. Giant cells in cortical tubers in tuberous sclerosis showing synaptophysin-immunoreactive halos. Brain and Development. 1997;19(1):21–24. doi: 10.1016/S0387-7604(96)00079-4. PubMed DOI

Mizuguchi M, Takashima S. Neuropathology of tuberous sclerosis. Brain and Development. 2001;23(7):508–515. doi: 10.1016/S0387-7604(01)00304-7. PubMed DOI

Grajkowska W, et al. Brain lesions in tuberous sclerosis complex. Review. Folia Neuropathol. 2010;48(3):139–149. PubMed

Fohlen M, et al. Refractory epilepsy in preschool children with tuberous sclerosis complex: Early surgical treatment and outcome. Seizure. 2018;60:71–79. doi: 10.1016/j.seizure.2018.06.005. PubMed DOI

Kalantari BN, Salamon N. Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging. AJR Am J Roentgenol. 2008;190(5):W304–W309. doi: 10.2214/AJR.07.2928. PubMed DOI

Yamanouchi H, et al. Evidence of abnormal differentiation in giant cells of tuberous sclerosis. Pediatr Neurol. 1997;17(1):49–53. doi: 10.1016/S0887-8994(97)00036-2. PubMed DOI

Henske EP, et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol. 1997;151(6):1639–1647. PubMed PMC

DiMario FJ., Jr Brain abnormalities in tuberous sclerosis complex. J Child Neurol. 2004;19(9):650–657. doi: 10.1177/08830738040190090401. PubMed DOI

Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology. 2004;63(8):1457–1461. doi: 10.1212/01.WNL.0000142039.14522.1A. PubMed DOI

Adriaensen ME, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol. 2009;16(696):691–6. doi: 10.1111/j.1468-1331.2009.02567.x. PubMed DOI

Cuccia V, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 2003;19(4):232–243. doi: 10.1007/s00381-002-0700-2. PubMed DOI

Buccoliero AM, et al. Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 2009;29(1):25–30. doi: 10.1111/j.1440-1789.2008.00934.x. PubMed DOI

Hirose T, et al. Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study. Acta Neuropathol. 1995;90(4):387–399. doi: 10.1007/BF00315012. PubMed DOI

Di Rocco C, Iannelli A, Marchese E. On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg. 1995;23(3):115–121. doi: 10.1159/000120947. PubMed DOI

Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–1356. doi: 10.1056/NEJMra055323. PubMed DOI

Kim JY, et al. Subependymal Giant Cell Astrocytoma Presenting with Tumoral Bleeding: A Case Report. Brain Tumor Res Treat. 2017;5(1):37–41. doi: 10.14791/btrt.2017.5.1.37. PubMed DOI PMC

Ess KC, et al. Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology. 2005;64(8):1446–1449. doi: 10.1212/01.WNL.0000158653.81008.49. PubMed DOI

Ess KC, et al. Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology. Glia. 2004;46(1):28–40. doi: 10.1002/glia.10324. PubMed DOI

Feng L, Hatten ME, Heintz N. Brain lipid-binding protein (BLBP): a novel signaling system in the developing mammalian CNS. Neuron. 1994;12(4):895–908. doi: 10.1016/0896-6273(94)90341-7. PubMed DOI

Jozwiak S, et al. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis. J Child Neurol. 2004;19(2):102–106. doi: 10.1177/08830738040190020401. PubMed DOI

Mizuguchi M, et al. Novel cerebral lesions in the Eker rat model of tuberous sclerosis: cortical tuber and anaplastic ganglioglioma. J Neuropathol Exp Neurol. 2000;59(3):188–196. doi: 10.1093/jnen/59.3.188. PubMed DOI

Takahashi DK, et al. Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex. Epilepsia. 2004;45(12):1525–1530. doi: 10.1111/j.0013-9580.2004.23004.x. PubMed DOI

Wenzel HJ, et al. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. Acta Neuropathol. 2004;108(2):97–108. doi: 10.1007/s00401-004-0865-8. PubMed DOI

Wippold FJ., 2nd A. Perry, and J. Lennerz, Neuropathology for the neuroradiologist: Rosenthal fibers. AJNR Am J Neuroradiol. 2006;27(5):958–961. PubMed PMC

Curatolo P, et al. Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:8–16. doi: 10.1111/j.1749-6632.1991.tb37743.x. PubMed DOI

Almobarak S, et al. Tuberous Sclerosis Complex: Clinical Spectrum and Epilepsy: A Retrospective Chart Review Study. Transl Neurosci. 2018;9:154–160. doi: 10.1515/tnsci-2018-0023. PubMed DOI PMC

Tschuluun N, Wenzel HJ, Schwartzkroin PA. Irradiation exacerbates cortical cytopathology in the Eker rat model of tuberous sclerosis complex, but does not induce hyperexcitability. Epilepsy Res. 2007;73(1):53–64. doi: 10.1016/j.eplepsyres.2006.08.003. PubMed DOI PMC

Cooper AJ. The role of glutamine synthetase and glutamate dehydrogenase in cerebral ammonia homeostasis. Neurochem Res. 2012;37(11):2439–2355. doi: 10.1007/s11064-012-0803-4. PubMed DOI PMC

Ito D, et al. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke. 2001;32(5):1208–1215. doi: 10.1161/01.STR.32.5.1208. PubMed DOI

Kirschstein T. Synaptic plasticity and learning in animal models of tuberous sclerosis complex. Neural Plast. 2012;2012:279834. doi: 10.1155/2012/279834. PubMed DOI PMC

Lee BH, Smith T, Paciorkowski AR. Autism spectrum disorder and epilepsy: Disorders with a shared biology. Epilepsy Behav. 2015;47:191–201. doi: 10.1016/j.yebeh.2015.03.017. PubMed DOI PMC

Switon K, et al. Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches. IUBMB Life. 2016;68(12):955–962. doi: 10.1002/iub.1579. PubMed DOI

Switon K, et al. Molecular neurobiology of mTOR. Neuroscience. 2017;341:112–153. doi: 10.1016/j.neuroscience.2016.11.017. PubMed DOI

Goorden SM, et al. Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures. Ann Neurol. 2007;62(6):648–655. doi: 10.1002/ana.21317. PubMed DOI

Ovsepian SV, et al. Ambient Glutamate Promotes Paroxysmal Hyperactivity in Cortical Pyramidal Neurons at Amyloid Plaques via Presynaptic mGluR1 Receptors. Cereb Cortex. 2017;27(10):4733–4749. PubMed

Ovsepian SV, O'Leary VB. Neuronal activity and amyloid plaque pathology: an update. J Alzheimers Dis. 2016;49(1):13–19. doi: 10.3233/JAD-150544. PubMed DOI

Ovsepian SV, et al. Amyloid Plaques of Alzheimer's Disease as Hotspots of Glutamatergic Activity. Neuroscientist. 2019;25(4):288–297. doi: 10.1177/1073858418791128. PubMed DOI PMC

von der Brelie C, et al. Impaired synaptic plasticity in a rat model of tuberous sclerosis. Eur J Neurosci. 2006;23(3):686–692. doi: 10.1111/j.1460-9568.2006.04594.x. PubMed DOI

Chu-Shore, C., et al., The natural history of epilepsy in tuberous sclerosis complex. , ed. Epilepsia. 2010, John Wiley & Sons, Ltd; 2010;51(7):1236–1241. PubMed PMC

Vignoli, A., et al., Epilepsy in TSC: Certain etiology does not mean certain prognosis. Epilepsia. . 2013: John Wiley & Sons, Ltd. PubMed

Kobayashi T, et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A. 2001;98(15):8762–8767. doi: 10.1073/pnas.151033798. PubMed DOI PMC

Uhlmann EJ, et al. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol. 2002;52(3):285–296. doi: 10.1002/ana.10283. PubMed DOI

Zeng LH, et al. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet. 2011;20(3):445–454. doi: 10.1093/hmg/ddq491. PubMed DOI PMC

Onda H, et al. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest. 1999;104(6):687–695. doi: 10.1172/JCI7319. PubMed DOI PMC

Way SW, et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet. 2009;18(7):1252–1265. doi: 10.1093/hmg/ddp025. PubMed DOI PMC

Crowell, B., et al., Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123). eNeuro, 2015. 2(6):ENEURO.0046-15.2015. 10.1523/ENEURO.0046-15.2015. PubMed PMC

Steele RJ, Morris RG. Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus. 1999;9(2):118–136. doi: 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8. PubMed DOI

Waltereit R, et al. Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats. Behav Genet. 2011;41(3):364–372. doi: 10.1007/s10519-010-9399-0. PubMed DOI

All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma